Brief: Daewoong Pharma Partners with Tufts Medical Center
29/10/2020 13:51
Oct 29 (Reuters) - Daewoong Pharma 069620.KS :
* DAEWOONG PHARMACEUTICAL PARTNERS WITH TUFTS MEDICAL CENTER
FOR
PHASE 2 CLINICAL TRIAL WITH NICLOSAMIDE
* DAEWOONG PHARMA - ENTERING PHASE 2 CLINICAL TRIAL IN
UNITED
STATES BASED ON TRIAL RESULTS IN SOUTH KOREA, INDIA, AND
AUSTRALIA
* DAEWOONG PHARMA - PLANNING PRE-IND MEETING WITH U.S. FDA
TO
APPLY FOR PHASE 2 CLINICAL TRIAL
* DAEWOONG PHARMA - PLANNING PRE-IND MEETING WITH U.S. FDA
ONCE
OBTAINING ETHNICITY-BASED SAFETY DATA SORTED FROM PHASE 1
CLINICAL STUDIES
Source text for Eikon: ID:nPnbqrcGva
Further company coverage: 069620.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Daewoong Pharma
See all newsBrief: Daewoong Pharma Q2 Operating. Profit 77 Billion Won, Up 23% Y/Y
Brief: Daewoong Pharma Wins 92.6 Billion Won Order
Brief: Daewoong Pharma Q4 Operating Profit 45.5 Billion Won, Up 9% From Year Earlier
Brief: Daewoong Pharma Q2 Operating Profit 62.5 Billion Won, Up 26% From Year Earlier
Brief: Daewoong Pharma Q1 Operating Profit 42 Billion Won, Up 34.5% From Year Earlier